By a News Reporter-Staff News Editor at Genomics & Genetics Weekly -- Research findings on Oncology are discussed in a new report. According to news originating from Olomouc, Czech Republic, by NewsRx correspondents, research stated, "Sodium butyrate, as a naturally occurring inhibitor of histone deacetylases (HDACI), is a non-toxic agent, with an ability to change histone acetylation and expression of large number genes. This study shows different effects of sodium butyrate on expression and transcription activity of the androgen receptor in cancer (LNCaP, C4-2) and normal (RWPE-1) prostate cells."
Our news journalists obtained a quote from the research from Palacky University, "Moreover, we studied the coregulator expressions and histone acetylation alteration in cancer and normal cells. Coregulators, coactivators as well as corepressors, play an important role in AR-mediated growth and progression of prostate cancer. There is a competition between coactivators and corepressors for binding on the AR and therefore the changes in coregulators expression and ratio could be important for prostate cancer survival. Our study was focused on two coregulators, SMRT and p300, which interact with AR in multiprotein complex and affect the AR transcription activity. Our data indicate that sodium butyrate has an effect on AR coregulators expression, transcription activity and histone acetylation in cancer cells, but there is only minimal effect in normal cells."
According to the news editors, the research concluded: "In addition, the results of changes in acetylation level on lysine residues of histone H4 after sodium butyrate treatment confirm its epigenetic effect on prostate cancer cells."
For more information on this research see: Different effect of sodium butyrate on cancer and normal prostate cells. Toxicology In Vitro, 2013;27(5):1489-95. (Elsevier - www.elsevier.com; Toxicology In Vitro - www.elsevier.com/wps/product/cws_home/800)
The news correspondents report that additional information may be obtained from L. Paskova, Laboratory of Molecular Pathology, Dept. of Clinical and Molecular Pathology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Hnevotinska 3, 775 15 Olomouc, Czech Republic. Additional authors for this research include K. Smesny Trtkova, B. Fialova, A. Benedikova, K. Langova and Z. Kolar (see also Oncology).
Keywords for this news article include: Europe, Olomouc, Genetics, Histones, Oncology, Butyrates, Butyric Acids, Czech Republic, Nucleoproteins, Prostate Cancer, Carboxylic Acids, Organic Chemicals, Prostatic Neoplasms.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC
To see more of the NewsRx.com, or to subscribe, go to http://www.newsrx.com .